Mazen Noureddin

机构：Houston Methodist, Methodist Hospital

发表论文 9 篇 · 总被引 154 次 · h-index 6

代表论文

• Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019 (2024 · Metabolism · 被引 63)
• Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria (2024 · Communications Medicine · 被引 53)
• Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis (2025 · Expert Opinion on Pharmacotherapy · 被引 13)
• Alcohol‐Attributable Cancer: Update From the Global Burden of Disease 2021 Study (2025 · Alimentary Pharmacology & Therapeutics · 被引 9)
• Mortality of Gastrointestinal Cancers Attributable to Smoking, Alcohol, and Metabolic Risk Factors, and its Association With Socioeconomic Development Status 2000-2021 (2025 · The American Journal of Medicine · 被引 9)
• 723: ONCE-MONTHLY EFIMOSFERMIN ALFA (BOS-580) IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS WITH F2/F3 FIBROSIS: RESULTS FROM A 24 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL (2025 · Gastroenterology · 被引 7)